MedTrace Logo

Exploration of Circular RNA in B-cell Hematologic Malignancies

NCT07774572 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-08-19

No results posted yet for this study

Summary

This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with R/R B-cell malignancies.

Conditions

  • Lymphoma, B-Cell Refractory

Interventions

DRUG

Investigational product (IP)

In Vivo Circular RNA Chimeric Antigen Receptor (CAR) T Cell Therapy

Sponsors & Collaborators

  • RiboX Therapeutics Ltd.

    collaborator INDUSTRY

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-26
Primary Completion
2027-03-31
Completion
2029-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07774572 on ClinicalTrials.gov